ZoomRx Launches AI-Powered Marketing Asset Testing Tool

BOSTON, Oct. 13, 2026 /CourierPR/ -- ZoomRx, a strategic life sciences consultancy trusted by 100+ leading biopharma companies, including 19 of the top 20, has launched a new marketing asset testing (MAT) tool. This AI-powered application, built on Sagan Agents, ZoomRx's agentic operating system for biopharma customer insights, aims to revolutionize how pharma brands develop and test their marketing materials.

Pharma marketing now spans dozens of channels, and generative AI allows teams to create far more asset variants than they can evaluate. However, traditional messaging studies take 8 to 12 weeks and produce a single, channel-agnostic ranked list. Testing a message as a banner, personalizing it for a segment, or putting it in the right story flow each requires another study. As a result, too often marketing creative goes to market on instinct and is validated late, if at all.

MAT, on the other hand, replaces the traditional messaging study with a series of cost-effective, focused studies. Each study answers the question in front of the brand team, with every result feeding the next round. Past studies and prior test results load into a Data Archive, so each new study starts from what the brand already knows. Teams build asset variants, refine them with synthetic audiences grounded in their own research, then validate the strongest with real HCPs from ZoomRx's panel. The same platform that finds the strongest messages customizes them to channels, personalizes them to segments, and puts them in the right flow. Assets can be tested in their final form, as HCPs will see them.

Agents draft the study design, build the survey, run quality checks, field the study, and analyze the results. A ZoomRx research expert reviews the design at each approval gate, and the brand team approves every set of messages or assets before it is tested with real HCPs. Studies typically take 1 to 2 days to set up and 5 to 7 days to field, with results delivered the day after fieldwork closes, in the application and as a downloadable deck and Excel file.

MAT is available now to US pharma and biotech brand teams as a 12-month subscription for one brand and indication, including platform access, fieldwork credits for testing with real respondents, and unlimited testing with synthetic HCPs during the subscription period. Teams can download the MAT white paper or request a walkthrough. ZoomRx is also offering a free Sagan Agents pilot through December 31, 2026, at zoomrx.com/offerings/sagan-agents.

MAT is backed by ZoomRx's 65,000+ HCP and patient panel, 700M+ proprietary benchmark data points, and 15+ years of life sciences research. Sagan Agents was named a finalist for the 2026 Fierce AI Innovation Awards in the Commercial Strategy and Launch category.